Calcipotriol and regression in T-cell lymphoma of skin

Scott-Mackie, P.; Hickish, Tamas; Mortimer, Peter; Sloane, J P; Cunningham, David

doi:10.1016/0140-6736(93)91373-t

Cited by 14 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin D has been shown to inhibit growth of human colon carcinoma cells (Shabahang et al, 1993) and to induce regression of T-cell lymphoma of the skin (Scott-Mackie et al, 1993). Receptors for vitamin D are present in a variety of cancer cell lines, including prostate carcinoma (Miller et al.…”

Section: Discussionmentioning

confidence: 99%

Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells

Zugmaier

Jager²,

Grage³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary Retinoids and vitamin D are important factors that regulate cellular growth and differentiation. An additive growth-inhibitory effect of retinoids and vitamin D analogues has been demonstrated for human myeloma, leukaemic and breast cancer cells. We set out to study the effects of the vitamin D analogue EB1089 and the retinoids all-trans-and 9-cis-retinoic acid on the human pancreatic adenocarcinoma cell lines Capan 1 and Capan 2 and the undifferentiated pancreatic carcinoma cell line Hs766T. The cell lines investigated expressed vitamin D receptor, retinoic acid receptor (RAR)-a and y as determined by polymerase chain reaction after reverse transcription. RAR-f, was expressed only in Hs766T cells. Addition of all-trans-retinoic acid increased the amount of RAR-a mRNA in the three cell lines and induced RAR-,B mRNA in Capan 1 and Capan 2 cells. All-trans-retinoic acid at a concentration of 10 nM inhibited the growth of Capan 1 and Capan 2 cells by 40% relative to controls. 9-cis-Retinoic acid was less effective. Neither all-trans-retinoic acid nor 9-cisretinoic acid affected the growth of Hs766T cells. EB1089, if added alone to the cells, did not significantly inhibit growth. However, the combination of 1 nM EB1089 with 10 nM all-trans-retinoic acid exerted a growthinhibitory effect of 90% in Capan 1 cells and of 70% in Capan 2 cells. Our data suggest that vitamin D analogues together with retinoids inhibit the growth of human pancreatic cancer cells. However, in vivo studies are necessary to examine the potential use of retinoids and vitamin D analogues on pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells

Zugmaier

Jager²,

Grage³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…32 A patient with high-grade angioimmunoblastic T-cell lymphoma entered remission with treatment but relapsed and then experienced a second remission. Several months later, she presented with erythematous, nonpruritic skin plaques over the anterior and posterior chest, axillae, and inner thighs.…”

Section: T-cell Lymphomamentioning

confidence: 98%

“…Vitamin D 3 and related compounds exert an antitumor effect in lymphomas by suppressing the production of growth-promoting lymphokines, such as interleukin-2, by activating T lymphocytes and interleukin-1 by monocytes, thereby inhibiting T-cell proliferation. 32 They also exert a direct inhibitory effect on immunoglobulin synthesis by activated B lymphocytes and indirectly by the inhibition of T-helper cells. These effects may be mediated through a speci®c vitamin D receptor.…”

Section: T-cell Lymphomamentioning

confidence: 99%

Nonpsoriatic Uses of Calcipotriol

Gupta

Browne

Bluhm

2002

Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology

View full text Add to dashboard Cite

show abstract

“…There is evidence that calcipotriene, only approved for psoriasis in the USA, is effective for other disorders involving keratinocytes (16)(17)(18)(19)23). This study found variation in the usage of calcipotriene over time as well as increasing off-label usage after its introduction; there were a total of 20 dermatologic diagnoses identified for which calcipotriene was used.…”

Section: Discussionmentioning

confidence: 99%

“…There is evidence for calcipotriene use for psoriasis subtypes such as pustular psoriasis, psoriasis in infancy (1), nail psoriasis, intertriginous psoriasis, and erythrodermic psoriasis (12)(13)(14). Over the last decade calcipotriene has also been advocated for other unrelated disorders of keratinization such as: mixed type acanthosis nigricans (15), congenital ichthyosis (16), cutaneous T-cell lymphoma (17), erythema annulare centrifugum (18), hereditary epidermolytic palmoplantar keratoderma, papillomatosis, and pityriasis rubra pilaris (19). Patients with diseases depending on off-label use of medications may experience barriers to accessing useful medications.…”

Section: Introductionmentioning

confidence: 99%

Trends in on and off‐label calcipotriene use

Pearce

Camacho

Balkrishnan³

et al. 2006

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Following its introduction in 1994, calcipotriene quickly became the single most prescribed medication for psoriasis according to National Ambulatory Medical Care Survey (NAMCS) data. Primarily through regulation of cellular differentiation, calcipotriene may be effective in dermatoses other than psoriasis. We characterize the clinical trends in the utilization of calcipotriene by analyzing a representative sample of visits to US physicians. Demographic characteristics, specialty of the provider, and off-label uses are reported. Calcipotriene was mentioned at 5.8 million of all NAMCS visits during the study period. Nearly 57% of mentions of calcipotriene were not linked to a diagnosis of psoriasis. Adjusted use for gender and race were relatively stable; there was a rise in non-psoriasis uses and use among non-dermatologists in 1997. Our findings support previous reports of the utility of calcipotriene in treating other dermatoses as witnessed by the numerous conditions for which its use was observed. Physicians and policy-makers should be aware of the role that this medication plays in the delivery of dermatologic care.

show abstract

Calcipotriol and regression in T-cell lymphoma of skin

Cited by 14 publications

References 8 publications

Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells

Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells

Nonpsoriatic Uses of Calcipotriol

Trends in on and off‐label calcipotriene use

Contact Info

Product

Resources

About